High Cost Drugs exc. from tariff

A number of high cost drugs, devices, procedures and products have been excluded from the scope of the national tariff of payment by results . Following the re-organisation of the NHS these drugs are commissioned by:

  • NHS England or
  • the Integrated Care Board

 

A detailed list of the NHS National Tariff Payment System for 2022 to 2023 is available here

A summary of PbR excluded from tariff drugs commissioned by ICB or NHSE is available here (2022-23)

A detailed list of medicines directly commissioned by NHS England is available here - (Version 17. 2022-23)

NHS England are the responsible commissioners for the management of the Cancer Drugs Fund. For details of the CDF click here

A list of technologies with approved Patient Access Schemes is available here

 

The Manual - this is a technical document describing the prescribed specialised services, some of these are directly commissioned by NHS England and some by ICBs

Commissioning intentions - this serves as notice to all providers of specialised services in England of changes and priorities for the coming year

Gain Sharing - principles for sharing the benefits associated with more efficient use of medicines not reimbursed through national tariff prices

 

A significant proportion of high cost drugs excluded from tariff are commissioned by Derbyshire in line with NICE Technology Appraisals.

Biologic algorithms for use in Dermatology, Gastroenterology, Ophthalmology, Rheumatology, Cardiology and Neurology are listed below:

Speciality
Last updated
 Cardiology  
      Primary hypercholesterolaemia and mixed dyslipidaemia October 2019
 Dermatology
      Atopic Dermatitis
March 2021
      Psoriasis
November 2021
Gastroenterology
      Crohn's Disease
August 2020
      Ulcerative Colitis
June 2022
 Neurology  
      Migraine March 2022
      Sodium oxybate November 2019
 Ophthalmology
      Age-Related Macular Degeneration (ARMD) July 2022
      Diabetic Macular Oedema (DMO) July 2022
      Macular Oedema due to BRVO/CRVO January 2020
      Non-Infectious Posterior Uveitis  September 2019
Osteoporosis  
      Romosozumab July 2022
 Rheumatology
      Ankylosing Spondylitis August 2021
      Psoriatic Arthritis July 2022
      Moderate Rheumatoid Arthritis August 2021
      Severe Rheumatoid Arthritis April 2021

 


 

 


 

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app